Amarin Corporation

Amarin Corporation P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Amarin Corporation (AMRN) as of Nov 17, 2026 is 46.10. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -10.02 — a change of -559.98% (higher).

P/CF

46.10

YoY

-559.98%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Amarin Corporation is 2025 46.10 . P/CF (Price-to-Cash-Flow Ratio) of Amarin Corporation was 2024 -10.02 . It decreases by -559.98% higher compared to the previous year.

The Amarin Corporation P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
-3.28 USD
Jan 1, 2019
-33.20 USD
Jan 1, 2020
-14.30 USD
Jan 1, 2021
-4.67 USD
Jan 1, 2022
-1.73 USD
Jan 1, 2023
45.02 USD
Jan 1, 2024
-10.02 USD
Jan 1, 2025
46.10 USD
The Amarin Corporation P/CF history
YEARP/CFYoY
46.10-559.98%
-10.02-122.27%
45.02-2,705.90%
-1.73-63.04%
-4.67-67.31%
-14.30-56.93%
-33.20+911.14%
-3.28-65.33%
-9.47+118.70%
-4.33+18.01%
-3.67-14.68%
-4.30—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amarin Corporation Stock analysis

What does Amarin Corporation do? Amarin Corporation PLC generates revenue primarily through the sale of Vascepa (icosapent ethyl) capsules, approved by the FDA for reducing triglyceride levels in patients with severe hypertriglyceridemia. The company sells Vascepa to wholesalers, regional wholesalers, and specialty pharmacy providers, collectively referred to as distributors, who then resell the product to retail pharmacies for patient and healthcare provider use. The MARINE indication, derived from the MARINE study, is the key approved use driving sales in the cardiovascular health segment. Amarin's commercial strategy centers on the Vascepa segment, focusing on the development and commercialization of this therapeutic. The firm's lead product, Vascepa, is positioned as an adjunct to diet for treating severe hypertriglyceridemia, targeting healthcare providers and patients through a distribution network of wholesalers and specialty pharmacies. This model ensures Vascepa reaches retail pharmacies where it is dispensed to end users. Amarin Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amarin Corporation stock

P/CF (Price-to-Cash-Flow Ratio) of Amarin Corporation is 46.10 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Amarin Corporation changed from -10.02 to 46.10, representing a -559.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Amarin Corporation since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Amarin Corporation with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Amarin Corporation

All Key Metrics — Amarin Corporation